Skip to main content
SpringerLink
Log in

Treatment of Chronic Hepatitis C Infection

  • Chapter
Chronic Viral Hepatitis

Part of the book series: Clinical Gastroenterology ((CG))

  • 109 Accesses

Abstract

Hepatitis C virus (HCV) infection often causes insidious and progressive liver injury in infected individuals. Acute infection is typically mild and subclinical, yet there is a high rate of chronicity after infection. As many as 55–85% of individuals who contract HCV infection will develop chronic infection and hepatitis. Of these, at least 20% will progress to cirrhosis after a 10–30 yr period, and are at risk to develop hepatocelluplar carcinoma (1). The estimated worldwide prevalence of chronic HCV infection is over 170 million (2–4), and 2.7–3.9 million are infected in the United States (5,6). Cirrhosis caused by HCV infection is currently the leading indication for liver transplantation in the United States (7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675.

    Article  PubMed  CAS  Google Scholar 

  2. Alter Mi. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5–14.

    Article  Google Scholar 

  3. Alter MJ, Sampliner RE. Hepatitis C and miles to go before we sleep. N Engl J Med 1989; 321: 1538–1540.

    Google Scholar 

  4. Kuo G, Choo QL, Alter HJ, et al. Assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–364.

    Article  PubMed  CAS  Google Scholar 

  5. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(Suppl 1): 62S–65S.

    Article  Google Scholar 

  6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C infection in the United States, 1988–1994. N Engl J Med 1999; 341: 556–562.

    Article  PubMed  CAS  Google Scholar 

  7. Harper AM, Rosendale JD, McBride MA, et al. UNOS OPTN waiting list and donor registry. Clin Transplant 1998; 73–90.

    Google Scholar 

  8. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997: 112: 463–472.

    Article  PubMed  CAS  Google Scholar 

  9. Davis GL. Recombinant alpha interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol1990;11(Suppl 1): S72—S75.

    Google Scholar 

  10. Davis GL, Hoofnagle JH. Interferon in viral hepatitis: role in pathogenesis and treatment. Hepatology 1986; 6: 1038–1041.

    Article  PubMed  CAS  Google Scholar 

  11. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 1575–1578.

    Article  PubMed  CAS  Google Scholar 

  12. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506.

    Article  PubMed  CAS  Google Scholar 

  13. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497–502.

    PubMed  CAS  Google Scholar 

  14. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–789.

    Article  PubMed  CAS  Google Scholar 

  15. Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995; 23: 487–496.

    Article  PubMed  CAS  Google Scholar 

  16. Poynard T, Bedo s sa P, Chevallier MA, et al. Comparison of three interferon alfa2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 322: 1457–1462.

    Article  Google Scholar 

  17. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 1993; 18: 1300–1305.

    Article  PubMed  CAS  Google Scholar 

  18. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780–785.

    Article  PubMed  CAS  Google Scholar 

  19. Castilla A. Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324: 933–940.

    Google Scholar 

  20. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–881.

    PubMed  CAS  Google Scholar 

  21. Reichard O, Glaumann H, Fryden A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783–787.

    Article  PubMed  CAS  Google Scholar 

  22. Schvarcz R, Glaumann H, Weiland O, et al. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991; 11: 30–38.

    PubMed  CAS  Google Scholar 

  23. Nelson DR, Lau JYN. Pathogenesis of chronic hepatitis C virus infection. In: Therapiesfor Viral Hepatitis (Schinazi RF, Sommadossi J-P, Thomas HC, eds.), London: International Medical, 1998; 8: 65–76.

    Google Scholar 

  24. Davis GL, Nelson DR, Reyes GR. Future options in the management of hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 103–112.

    PubMed  CAS  Google Scholar 

  25. Bodenheimer HC, Lefkowitch J, Lindsay K, et al. Histological and clinical correlation in chronic hepatitis C. Hepatology 1990; 12: 844A.

    Google Scholar 

  26. Schoeman MN, Liddle C, Bilous M, et al. Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease pregression. Aust NZ J Med 1990; 20: 56–62.

    Article  CAS  Google Scholar 

  27. Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenerol Hepatol 1999; 14(Suppl): S14–S18.

    Google Scholar 

  28. EASL International Consensus Conference on Hepatitis C. Paris, 26–28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956–961.

    Google Scholar 

  29. Peters M, Davis GL, Dooley JS, et al. Interferon system in acute and chronic viral hepatitis. In: Progress in Liver Diseases (Popper H, Schaffner F, eds.), Grune and Stratton, New York, NY, 1996; 8: 453–467.

    Google Scholar 

  30. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24: 1034–1040.

    PubMed  CAS  Google Scholar 

  31. Gross JB, Brandhagen DJ, Poterucha JJ, et al. Daily high dose interferon suppresses viremia in patients with chronic hepatitis C without a previous sustained response. Gastroenterology 1998; 114: 1248A.

    Google Scholar 

  32. Métreau JM, Calmus Y, Poupon R, et al. Twelve month treatment compared to 6-month treatment does not improve the efficacy of alpha-interferon in NANB chronic active hepatitis. Hepatology 1991; 14: 72A.

    Google Scholar 

  33. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  34. Glue P. Clinical pharmacology of ribavirin. Semin Liver Dis. 1999; 19(Suppl 1): 17–24

    PubMed  CAS  Google Scholar 

  35. Dusheiko G. Side effects of interferon alpha in viral hepatitis C. Hepatology 1997; 26(Suppl 1): 112S–121S.

    Article  Google Scholar 

  36. Crumpacker CS. Overview of ribavirin treatment of infection caused by RNA viruses. In: Clinical Applications of Ribavirin (Smith RA, Knight V, Smith JAD, eds.), Orlando, Academic, 1984, pp. 33–38.

    Google Scholar 

  37. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990; 12: 1132–1346.

    Google Scholar 

  38. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563–570.

    Article  PubMed  CAS  Google Scholar 

  39. Davis GL. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 49–55.

    Article  PubMed  CAS  Google Scholar 

  40. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH 1 cytokine production, but inhibits TH2 cytokine response. J Immunol 1998; 160: 3487–3493.

    PubMed  CAS  Google Scholar 

  41. Pawlotsky JM, Dahari H, Conrad A, et al. Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus genotype lb replication kinetics and clearance. Hepatology 1998; 28: 288A.

    Google Scholar 

  42. Ilyin GP, Langouet S, Rissel M, et al. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes. Hepatology 1998; 27: 1687–1694.

    Article  PubMed  CAS  Google Scholar 

  43. Martin J, Navas S, Quiroga JA, et al. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10: 635–644.

    Article  PubMed  CAS  Google Scholar 

  44. Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebocontrolled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 352: 83–87.

    Article  Google Scholar 

  45. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  46. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in treatment of chronic hepatitis C. Gastroenterology 1996; 1 I 1: 1307–1312.

    Google Scholar 

  47. Chemello L, Cavalletto L, Bernardinello E, et al. Effect of interferon alfa and ribavirin combination therapy in naive patients wtih chronic hepatitis C. J Hepatol 1995; 23(Suppl 2): 8–12.

    PubMed  CAS  Google Scholar 

  48. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961–966.

    Article  PubMed  CAS  Google Scholar 

  49. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 57–65.

    PubMed  CAS  Google Scholar 

  50. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493–1499.

    Article  PubMed  CAS  Google Scholar 

  51. Lau DTY, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–1127.

    Article  PubMed  CAS  Google Scholar 

  52. Davis GL, McHutchison J, Poynard T, Esteban-Mur R, for the International Hepatitis Interventional Therapy Group. Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C. Hepatology 1999; 30: 303A.

    Google Scholar 

  53. Neumann AU, Dahari H, Conrad A, et al. Early prediction and mechanism of the ribavirin/IFN-α dual therapy effect on chronic hepatitis C virus (HCV) infection. Hepatology 1999; 30: 309A.

    Google Scholar 

  54. Poynard T, McHutchinson J, Goodman Z, et al. Is an “a la carte” combination interferonal alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211–218.

    Article  PubMed  CAS  Google Scholar 

  55. Cammà C, Giunta M, Pinzello G, et al. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analysis of randomized controlled trials. Am J Gastroenterology 1999; 94: 581–595.

    Google Scholar 

  56. Davis GL, Lindsay K, Albrecht J, et al. Clinical predictors of response to recombinant alpha interferon treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. J Viral Hepatol 1994; 1: 55–63.

    Article  CAS  Google Scholar 

  57. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet 1993; 341: 1501–1504.

    Article  PubMed  CAS  Google Scholar 

  58. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–1056.

    Article  PubMed  CAS  Google Scholar 

  59. Davis GL. Treatment of acute and chronic hepatitis C. Clin Liver Dis 1997; 1: 615–630.

    Article  PubMed  CAS  Google Scholar 

  60. Alberti A, Chemello L, Noventa F, et al. Therapy of hepatitis C: retreatment with alpha interferon. Hepatology 1997; 26(Suppl 1): 137S–142S.

    Article  Google Scholar 

  61. Picciotti A, Brizzolara R, Campo N, et al. Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis (abstract). Hepatology 1996; 24: 273A.

    Google Scholar 

  62. Le X, Zhou X, Dai X, et al. Evaluation of interferon-2b for the treatment of relapsed hepatitis C. Hepatology 1996; 24: 536.

    Google Scholar 

  63. Craxi A, Almasio P, Fuschi P, et al. Should patients with chronic hepatitis C who relapse after interferon be retreated? J Hepatol 1997; 26: 192A.

    Google Scholar 

  64. Heathcote EJ, Keeffe EB, Lee SS, et al. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27: 1136–1143.

    Article  PubMed  CAS  Google Scholar 

  65. Cammà C, Giunta M, Chemello L, et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology 1999; 30: 801–807.

    Article  PubMed  Google Scholar 

  66. Bellobuono A, Mondazzi L, Tempini S, et al. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepatol 1997; 4: 185–191.

    Article  CAS  Google Scholar 

  67. Brillanti S, Garson J, Foli M, et al. Pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812–817.

    Article  PubMed  CAS  Google Scholar 

  68. Pol S, Couzigou P, Bourliere M, et al. A randomized trial of ribavirin and interferonalpha vs interferon alpha alone in patients with chronic hepatitis C who were nonresponders to a previous treatment. J Hepatol 1999; 31: 1–7.

    Article  PubMed  CAS  Google Scholar 

  69. Davis GL. Combination treatment with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Clin Liver Dis 1999; 19(Suppl 1): 49–55.

    Article  CAS  Google Scholar 

  70. Di Marco V, Almasio P, Vaccaro A, et al. Combined treatment of relapse of chronic hepatitis C with high dose α-2B interferon plus ribavirin for 6 or 12 months. Hepatology 1999; 30: 303A.

    Google Scholar 

  71. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Hepatology 1997; 26(Suppl 1): 101S–107S.

    Article  Google Scholar 

  72. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26(Suppl 1): 71S–77S.

    Article  Google Scholar 

  73. Bacon BR. Available options for treatment of interferon nonresponders. Am J Med 1999; 107: 67S–70S.

    Article  Google Scholar 

  74. Montalto G, Tripi S, Cartabellotta A, et al. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterology 1998; 93: 950–953.

    CAS  Google Scholar 

  75. Schalm SW, Brouwer JT, Chemello L, et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1996; 41(Suppl 12): 131S–134S.

    Article  Google Scholar 

  76. Schalm SW, Brouwer JT. Antiviral therapy of hepatitis C. Scand J Gastroenterol 1997; 223(Suppl): 46–49.

    CAS  Google Scholar 

  77. Davis GL. Current therapy for chronic hepatitis C. Gastroenterology 2000; 118 (Suppl 1): S104–S114.

    Article  Google Scholar 

  78. Brass CA. Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection. Clin Ther 1998; 20: 388–397.

    Article  PubMed  CAS  Google Scholar 

  79. Sjogren MH, Holzmuller K, Kadakia S, et al. High response rate to interferon/ribavirin treatment in HCV relapsers but not in non-responders. Hepatology 1998; 28: 287A.

    Google Scholar 

  80. Heathcote EJ, James S, Mullen K, et al. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. Hepatology 1999; 30: 562–566.

    Article  PubMed  CAS  Google Scholar 

  81. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C: relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19: 67–75.

    PubMed  CAS  Google Scholar 

  82. Weisz CK, Kreiswirth S, McMeeking M, et al. Erythropoietin use for ribavirin/ interferon induced anemia in patients with hepatitis (abstract). Hepatology 1998; 28: 288A.

    Google Scholar 

  83. Lau JYN, Davis GL, Brunson ME, et al. Hepatitis C in kidney transplant recipients. Hepatology. 1993; 18: 1027–1031.

    Article  PubMed  CAS  Google Scholar 

  84. Neumann AU, Conrad A, Pianco S, McHutchison J. Early prediction and mechanism of the ribavirin/IFN dual therapy effect on chronic hepatitis C virus infection. Hepatology 1999; 30: 309A.

    Google Scholar 

  85. Bukh J, Purcell R, Miller R. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 1992; 89: 187–191.

    Article  PubMed  CAS  Google Scholar 

  86. Busch MP, Wiber JC, Johnson P, et al. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1992; 32: 420–425.

    Article  PubMed  CAS  Google Scholar 

  87. Cristiano K, Di Bisceglie A, Hoofnagle J, et al. Hepatitis C RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Hepatology 1991; 14: 51–55.

    Article  PubMed  CAS  Google Scholar 

  88. Wang JT, Wang TH, Sheu JC, et al. Effects of anticoagulants and storage of blood samples on efficacy of the polymerase chain reaction assay for hepatitis C virus. J Clin Microbiol 1992; 30: 750–753.

    PubMed  CAS  Google Scholar 

  89. Schiff ER, DeMedina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 3–15.

    PubMed  Google Scholar 

  90. Stuyver L, Rossau R, Maertens G, et al. Line probe assays for the deduction of hepatitis B and C virus genotypes. Antiviral Ther 1996; 124(Suppl 3): 868–876.

    Google Scholar 

  91. Shiffman M, Pockros P, Reddy RK, et al. Controlled, randomized, multicenter descending dose phase II trial of pegylated interferon alfa-2A vs standard interferon alfa-2A for treatment of chronic hepatitis C. Gastroenterology 1999; 116: A1275.

    Article  Google Scholar 

  92. Heathcote EJ, Shiffman M, Cooksley G, et al. Multinational evaluation of the efficacy and safety of once weekly PEG-interferon α-2A in patients with chronic hepatitis C with compenstaed cirrhosis. Hepatology 1999; 30: 316A.

    Google Scholar 

  93. Krawczynski K, Fattom A, Spelbring J, et al. Early termination of HCV infection by passive anti-HCV transfer in experimentally infected chimpanzees. Hepatology 1998; 28: 398A.

    Google Scholar 

  94. Dimasi N, Martin F, Volpari C, et al. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity-selected from human pacreatic secretory trypsin inhibitor and minibody repertoires. J Virol 1997; 71: 7461–7469.

    PubMed  CAS  Google Scholar 

  95. Blatt LM, Macejak DG, Lee Pa, et al. Antiviral activity and liver localization of nuclease resistant ribozymes directed against hepatitis C virus RNA. Antiviral Ther 2000; 5(Suppl 1): 50.

    Google Scholar 

  96. Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitisi C: a pilot trial in interferon nonresponders. Gastroenterology 2000; 118; 655–660.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Manal F. Abdelmalek MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary L. Davis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

    Raymond S. Koff MD

  2. Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA

    George Y. Wu MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Abdelmalek, M.F., Davis, G.L. (2002). Treatment of Chronic Hepatitis C Infection. In: Koff, R.S., Wu, G.Y. (eds) Chronic Viral Hepatitis. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-104-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-104-6_8

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4772-0

  • Online ISBN: 978-1-59259-104-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation